31/08/2026 Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases Lilly announced 1-year Ph3b data on ixekizumab and tirzepatide used together in adults with psoriatic disease and obesity Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases (Ref) Eli Lilly and Company and Merida Biosciences announced a definitive agreement for Lilly to acquire Merida Biosciences, a biotechnology